Microsphere drug delivery system for sustained intraocular release

Patent metadata

Field	Value
Publication number	US-9504653-B2
Application number	US-201414213294-A
Country	US
Kind code	B2
Filing date	Mar 14, 2014
Priority date	Apr 1, 2013
Publication date	Nov 29, 2016
Grant date	Nov 29, 2016

Abstract

Disclosed are biodegradable microspheres between 40 μm and 200 μm in diameter that are effectively retained in the anterior chamber of the eye without producing hyperemia. The microspheres generally contain a drug effective for the treatment of an ocular condition and include a biodegradable polymer matrix that can provide for the sustained (>7 day) release of the drug following administration to the anterior chamber of the eye. Methods for making and using the microspheres to treat an ocular condition are also disclosed.

First claim

What is claimed is:

1. A drug delivery system effective for the treatment of an ocular condition,
the system comprising a plurality of biodegradable microspheres and an ophthalmically acceptable carrier;
the biodegradable microspheres having diameters no less than about 130 microns and no greater than about 160 microns and comprising a biodegradable polymer matrix and a therapeutic agent effective for the treatment of the ocular condition;
and
wherein the drug delivery system releases a therapeutically effective amount of the therapeutic agent for at least one week after the system is placed in an eye of a patient.

2. The drug delivery system according to claim 1 , wherein the microspheres present in the drug delivery system are produced by an emulsion process.

3. The drug delivery system according to claim 1 , wherein the ocular condition is glaucoma, elevated intraocular pressure, neovascularization, or inflammation.

4. The drug delivery system according to claim 3 , wherein the therapeutic agent is a prostamide, prostaglandin, steroidal anti-inflammatory agent, non-steroidal anti-inflammatory agent, alpha 2 adrenergic receptor agonist, or tyrosine kinase inhibitor.

5. The drug delivery system according to claim 4 , wherein the ocular condition is glaucoma or an inflammation of the eye of the patient and the therapeutic agent is bimatoprost, a steroidal anti-inflammatory agent, or a non-steroidal anti-inflammatory agent.

6. The drug delivery system according to claim 5 , wherein the ocular condition is glaucoma or elevated intraocular pressure and the therapeutic agent is bimatoprost and the drug delivery system comprises no therapeutic agent other than bimatoprost.

7. The drug delivery system according to claim 4 , wherein the therapeutic agent is a compound having the formula:

8. The drug delivery system according to claim 1 , wherein the ophthalmically acceptable carrier is an aqueous liquid or gel comprising a hyaluronic acid, a sodium hyaluronate, a hydroxyethyl cellulose (HEC), a carboxymethylcellulose (CMC), a hydroxypropylmethyl cellulose (HPMC), a polyvinylproline (PVP), or a pluronic polymer.

9. The drug delivery system according to claim 8 , wherein the ophthalmically acceptable carrier is an aqueous gel comprising 2.5% w/v sodium hyaluronate.

10. The drug delivery system according to claim 8 , wherein the biodegradable polymer matrix comprises a poly(D,L-lactide), a poly(D,L-lactide-co-glycolide), or a mixture thereof.

11. The drug delivery system according to claim 10 , wherein each said poly(D,L-lactide) and poly(D,L-lactide-co-glycolide) is independently selected from the group consisting of R203S, R203H, RG752H, RG755, RG502, RG502H, RG752S, R202H, R202S, and RG753S.

12. The drug delivery system according to claim 11 , wherein the biodegradable polymer matrix further comprises a polyethylene glycol (PEG).

13. The drug delivery system according to claim 12 , wherein the PEG is PEG 3350, PEG 4400, or PEG 8000.

14. The drug delivery system according to claim 12 , wherein the therapeutic agent is bimatoprost and the ocular condition is glaucoma.

15. The drug delivery system according to claim 1 , wherein the plurality of microspheres have a polydispersity of not more than about 5, wherein the polydispersity is the microsphere particle size distribution measured by d90/d10,
wherein d90 is the diameter below which 90% of the particles fall, and d10 is the diameter below which 10% of the particles fall.

16. The drug delivery system according to claim 1 , wherein the microspheres are effectively retained in the anterior chamber of the eye of the patient without producing hyperemia.

17. The drug delivery system according to claim 1 , wherein the patient is a human.

Assignees

• Allergan Inc

Inventors

• Liu Hui
• Wan Jinping
• Hughes Patrick M

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P27/06

  Antiglaucoma agents or miotics · CPC title

• A61P27/02

  Ophthalmic agents · CPC title

• A61K9/0048

  Eye, e.g. artificial tears · CPC title

• A61K31/165

  having aromatic rings, e.g. colchicine, atenolol, progabide · CPC title